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Abstract
As single agents, ABT-263 and ABT-737 (ABT), molecular antagonists of the Bcl-2 family, bind tightly to Bcl-2, Bcl-xL and Bcl-
w, but not to Mcl-1, and induce apoptosis only in limited cell types. The compound 2-deoxyglucose (2DG), in contrast,
partially blocks glycolysis, slowing cell growth but rarely causing cell death. Injected into an animal, 2DG accumulates
predominantly in tumors but does not harm other tissues. However, when cells that were highly resistant to ABT were pre-
treated with 2DG for 3 hours, ABT became a potent inducer of apoptosis, rapidly releasing cytochrome c from the
mitochondria and activating caspases at submicromolar concentrations in a Bak/Bax-dependent manner. Bak is normally
sequestered in complexes with Mcl-1 and Bcl-xL. 2DG primes cells by interfering with Bak-Mcl-1 association, making it easier
for ABT to dissociate Bak from Bcl-xL, freeing Bak to induce apoptosis. A highly active glucose transporter and Bid, as an
agent of the mitochondrial apoptotic signal amplification loop, are necessary for efficient apoptosis induction in this system.
This combination treatment of cancer-bearing mice was very effective against tumor xenograft from hormone-independent
highly metastasized chemo-resistant human prostate cancer cells, suggesting that the combination treatment may provide
a safe and effective alternative to genotoxin-based cancer therapies.
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Introduction
2-Deoxy-D-glucose is a glucose molecule which has the 2-
hydroxyl group replaced by hydrogen. 2DG is transported across
the plasma membrane by a glucose transporter [1]. Once in the
cytosol, 2DG is phosphorylated by hexokinase II and its product,
2-deoxyglucose 6-phosphate, is trapped in the cytosol and
becomes an inhibitor of hexokinases, just as glucose becomes
glucose 6-phosphate and becomes an inhibitor of hexokinases.
However, as glucose 6-phosphate is hydrolyzed by glucose 6-
phosphatase very rapidly, producing NADPH and generating
energy, its counterpart, 2-deoxyglucose 6-phosphate, is a poorer
substrate of glucose 6-phosphatase. Consequently 2-deoxyglucose
6-phosphate accumulates in the cytosol, inhibiting hexokinases
and lowering cellular energy levels. It is estimated that the
intracellular half-life of 2-deoxyglucose 6-phsophate is approxi-
mately 50 min in cancer cells [2]. Thus 2DG acts as an inhibitor of
the glycolytic pathway.
The slower hydrolysis rates of 2-deoxyglucose 6-phsophate
allow for glucose uptake to be measured in living animals by
18F-
fluoro-2-deoxyglucose based Positron Emission Tomography
(FDG-PET). Recent advances in FDG-PET has clearly shown
much higher rates of glucose transporter activities in vivo, of
almost all solid tumors compared to normal healthy tissues,
confirming the Warburg Effect [1]. FDG-PET has also become a
very sensitive way to detect tumors at a very early stage, e.g., early
stage asymptomatic pancreatic cancer. Since 2DG accumulates
predominantly in cancer cells and partially inhibits much-utilized
glycolysis in these cells, administration of 2DG is a safe and
effective way of slowing cancer growth [1]. However, the cytostatic
activity of 2DG is generally short-lived, lasting only about a week
[3]. Thus 2DG has been tried in combination with other
chemotherapeutics, but again with mixed results. In some cases,
it could lower the efficacy of other treatments [4]. One reason for
decreased efficacy in these combination therapies might be that in
some cells, 2DG activates an insulin-like growth factor receptor
(IGFR), which could activate the PI3K-mTOR-AKT pro-survival
pathway [5,6].
Various drugs that target Bcl-2 and Mcl-1 have been tested for
their abilities to induce apoptosis in cancer cells [7]. The most
prominent among them are the Bcl-2 antagonists ABT-737 and
ABT-263 [8,9]. ABT-737 binds specifically and with high affinity
to the Bcl-2 family of proteins, including Bcl-2, Bcl-xL and Bcl-w,
but not to Mcl-1. ABT-737 was modified at three sites to create
ABT-263 for improved oral bioavailability without the loss of
affinity to the Bcl-2 family of proteins [9]. As a single agent,
however, ABT-263/737 (ABT) induces apoptosis only in limited
tumor types, such as lymphomas and some small cell lung
carcinomas [8,9,10]. The reason for varied sensitivities to ABT is
not entirely clear.
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which cytochrome c is released from mitochondria in a Bax/Bak-
dependent manner, activating apoptosomes in the cytosol, or the
extrinsic pathway, in which caspases are activated directly
downstream of death receptors (reviewed by Salvesen & Riedl
[11]). Often there is cross-talk between these two pathways.
Because ABT binds mitochondrial proteins, ABT-induced apop-
tosis is thought to occur through the intrinsic pathway, but we do
not know exactly how this is done.
The critical step in the intrinsic pathway of apoptosis is when
cytochrome c is released from mitochondria because once
cytochrome c is released into cytosol, it stimulates the formation
of apoptosomes, the death executioner. For this reason, cyto-
chrome c release is often called the point of no return [12]. Until
several years ago, it was thought that calcium-activated mito-
chondria permeability transition pores (mPTP) may be required
for cytochrome c release during the intrinsic pathway of apoptosis.
However, it was shown that tBid-induced cytochrome c release
and subsequent apoptosis could take place in the absence of
VDAC [13] and cyclophilin D [14,15], two essential components
of the mPTP (reviewed in Yamaguchi & Perkins [16]). Instead, the
prevailing dogma is that cytochrome c release occurs through
mitochondrial outermembrane pores (MOMPs). Although
MOMP is a well-established concept, its existence remains
hypothetical because unlike nuclear pores or mPTP, there are
no EM pictures of MOMPs. Likewise, MOMPs have not been
isolated as a biological entity. Thus, it is not known whether Bak or
Bax reside in MOMPs. The most detailed analysis of MOMP
formation during apoptosis, came from studying lipid vesicles
assembled with mitochondrial outermembrane proteins. In these
studies, tBid-activated Bax was used to stimulate MOMP assembly
on the vesicles [17], stimulating the release of proteins as large as
2000 kDa [18] through pores with diameters of 25–100 nm [19].
If MOMPs on mitochondria are about the same size, one would
expect to see them using electron microscopy (EM), but they
haven’t been imaged. Thus, the existence of MOMPs remains
hypothetical. Nevertheless, from a mechanistic viewpoint, the
existence of MOMPs comprised either wholly or in part by Bax
and Bak makes sense.
BH3-only proteins such as tBid, BimS are called ‘‘activators’’
because they directly interact with Bax or Bak, changing their
conformation and inducing oligomerization, in other words
‘‘activating’’ them, leading to cytochrome c release and apoptosis.
More recent findings, however, suggest another scenario in which
apoptosis takes place in the absence of activator proteins. First,
Huang and colleagues showed that Bak is normally sequestered by
Mcl-1 and Bcl-xL, and Bak must be released from both before it
can form oligomers [20]. The idea that inactivating some anti-
apoptotic proteins without the help from some activator can
induce apoptosis, is not without controversy [21,22]. We favor the
idea because Huang and colleagues found that inactivating both
Bcl-xL and Mcl-1 was enough to induce apoptosis in Bid and Bim
knockout MEFs [23], and Hayashi and colleagues found the same
in Bid and Bim deficient platelet cells [24].
Assuming that Bim and Bid are not involved in ABT-induced
apoptosis, we can speculate reasons for varied sensitivities to ABT-
737. Since ABT-737 binds to Bcl-xL, inactivating it, but it does not
bind to Mcl-1, if there are less Mcl-1 proteins present, then the
efficacy of ABT-737 must increase. Indeed, Huang and colleagues
found that by depleting Mcl-1 from HeLa cells with siRNA, they
became sensitive to ABT-737 [25]. Many groups also reported
inverse correlations between cancer cell sensitivity to ABT-737
and Mcl-1 expression levels in many cancer types (see Information
S1). However, there are exceptions; HL-60 human promyerlocytic
leukemia cells express reasonably large amounts of Mcl-1, but they
are nevertheless, sensitive to ABT-737 [26]. Thus how ABT-737
induces apoptosis in some cancer cells and not in others, remains
poorly understood.
We initiated this project in order to search for agents that can
increase the efficacy of ABT. When we co-treated human tumor
cell lines with ABT and drugs that interfere with cancer specific
cellular metabolism, we found that 2DG pre-treatment vastly
improved the efficacy of ABT without harming healthy cells. We
show that 2DG-ABT induces apoptosis without altering Mcl-1
levels in ABT-resistant cells. When cancer cells resistant to ABT
are pre-treated with 2DG, the protein levels of Mcl-1 remain the
same, but Bak-Mcl-1 association is lost, sensitizing cells for ABT-
induced apoptosis. How 2DG treatment of cancer cells disrupts
Bak-Mcl-1 is not known. Thus, cancer cell sensitivity to ABT
seems to be determined not only by the protein levels of Mcl-1,
but also by how much Bak is sequestered by its association with
Mcl-1.
Results
2DG-ABT efficiently induces apoptosis of cancer cells
Applied as a single agent, 30 nM of ABT-737 killed 90% of
RS(4;11) non-Hodgkin’s B-cell lymphoma cells in 9 hours
(Fig. 1a). However, a 1-hour pre-incubation of RS(4;11) cells
with 5 to 10 mM 2DG in medium containing 10 mM glucose
increased the efficiency of ABT dramatically, killing 90% of
cells with just 3 nM ABT-737. 2DG alone did not cause cell
death during the 10-hour incubation. When we tested for
caspase activation, it was found that as little as 1 nM of ABT-
737 could activate caspases in 3 hours as long as the cells were
pre-incubated with 2DG for 3 hours. No caspase activation
beyond the background was observed in cells that were
incubated with 2DG alone. Thus, it can be concluded that
2DG sensitizes RS(4;11) cells to ABT-induced apoptosis. We
repeated the experiment using various concentrations of ABT-
263 and counted cells by trypan-blue dye to score for dead cells
24 hours after ABT addition (Fig. S1a). The result also showed
a synergistic effect of 2DG and ABT.
Next, we tested whether 2DG could sensitize ABT-resistant
tumor cells to ABT-737 or ABT-263. Initial experiments were
performed using HeLa cervical cancer cells. HeLa cells were pre-
treated for 1 hour with 2DG before the addition of ABT-737.
Nine hours after the addition of 1 mM of ABT-737, approximately
35% of HeLa cells that were pre-treated with 2DG, were Annexin
V-positive (Fig. 1b). This rate of cell death was comparable to that
seen after the treatment of HeLa cells with 1 mM staurosporine
(STS), a well-known inducer of apoptosis in HeLa cells In another
set of experiments, when HeLa cells were pre-treated for 3 hours
with 10 mM 2DG in a medium containing 25 mM glucose, robust
caspase activation was observed within 3 hours at concentrations
of ABT-737 as low as 0.1 mM (Fig. 1c). Without 2DG pre-
treatment, even 10 mM ABT-737 could not activate caspases
during the same period. This experiment was also repeated using
ABT-263 and scoring dead cells with trypan-blue dye incorpora-
tion (Fig. S1b). Again, it showed a synergistic effect of ABT-263
and 2DG. ABT-737 and ABT-263 were compared side-by-side
using three-hour 2DG-pretreatment of HeLa cells. ABT-263 was
slightly better than ABT-737 in inducing apoptosis (Fig. S2a).
Conditions for 2DG-ABT induced apoptosis
Kinetic and dose-response studies with HeLa cells showed the
following: (i) the presence of glucose in the medium is necessary for
2DG-ABT induced apoptosis (Fig. S2b), and the optimal molar
2DG-ABT Combination Therapy
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0.4 to 1.0; (ii) 2DG should be added 3 to 4 hours prior to the
addition of ABT (Fig. S2c & d); and (iii) caspase activation is
observed within 3 hours of ABT addition. These conditions may
reflect the stability of ABT-263/737 in solution (approximately
4 hours [9]), as well as the nature of intercellular signals generated
by 2DG; it must take 3 to 4 hours for 2DG to generate a strong
enough signal to be effective. Under these conditions, the
reduction in cellular ATP concentration is very slight (Fig. 5a),
suggesting that ATP insufficiency does not provide an explanation
for the improved sensitivity to ABT-737 and ABT-263.
All subsequent experiments were performed using the following
conditions: Add 5–10 mM 2DG to cell culture. Three hours later,
add 1–3 mM ABT. Assay for caspase activity and cytochrome c
release from mitochondria three hours after ABT-treatment. Six
hours after ABT-treatment, assay for Annexin V staining.
24 hours later, count viable cells by trypan blue dye exclusion
assay. The response to the protocol varied from cell line to cell
line. Among cancer cells that responded well were breast cancer
cell line MCF-7 and hormone resistant prostate cancer cell line
PPC-1. In both cases, over 95% of cells were eliminated in
24 hours by the combination treatment (Fig. 1d). A single agent
application of 2DG caused some death (31.3% for HeLa, none
observed in MCF-7, and 21.5% for PPC-1). Since all cells have
varied amounts of glycogen as stored source of glucose, the rates of
cell death by 2DG was largely dependent on the previous history
of cultured conditions. Cultured cells normally overcome 2DG-
induced growth-arrest and start to grow in 24–48 hours (data not
shown). Furthermore, when 2DG was injected into cancer-bearing
mice, it did not cause tumor regression, but delayed tumor growth
by 5–6 days. After this short delay, tumors started to grow. Other
groups had made similar observations [4]. The reason for the
acquired resistance to 2DG is not known. As a single agent, the
effect of ABT-263 was also marginal (13.7% for HeLa, 3.1% for
Figure 1. Annexin V-staining of 2DG-ABT treated RS(4;11) and HeLa cells. a, RS(4;11) cells pre-treated with 20 mM fructose or 0–10 mM 2-
deoxy-D-glucose in regular RPMI medium containing 12 mM glucose, for 1 hour before the addition of ABT-737 at indicated concentrations. 9 hours
later, cells were analyzed by FACS for Annexin-V positivity. Chi Square Test of Independence for two variables, 2DG and ABT, was
P(x˜1
2.193.35)=0.000000. Since the combination was clearly better than expected values, the statistic suggests synergistic interaction between
2DG and ABT-737. b, HeLa cells were pre-treated for 1 hour either with or without 10 mM deoxyglucose in DMEM containing 12 mM glucose, before
adding ABT-737. Six hours later, cells were analyzed by FACS for Annexin-V staining. c, HeLa cells were pre-treated for 3 hours with 2DG before the
addition of ABT-737. Cells were assayed for caspase activity at 3 hours after ABT-737 addition. d, HeLa, PPC-1 and MCF-7 cells were treated with
10 mM 2DG for 3 hours before adding 1 mM ABT-263 for overnight incubation. Trypan blue-negative (viable) cells were counted and graphed (mean
6 std dev; n=3). e, Combination therapy reduces clonogenic survival of PPC-1 cells. PPC-1 cells were treated just once for 24 hrs with 5 mM
2DG, 1 mM ABT-263, both, or were left untreated. 250–1000 cells were plated per 30 mm dish, and 12 days later, surviving cell colonies were stained.
doi:10.1371/journal.pone.0024102.g001
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combination far exceeded the additive effects of 2DG and ABT
in all three cell lines (HeLa expected viable cells 59%, observed
25%, MCF7 expected viable cells 115%, observed 3.8%, and
PPC1 expected viable cells 49.7%, observed 3.9%). The
Clonogenic Cell Survival assay also showed that over 95% of
PPC-1 cells were eliminated by just one treatment while single
agent applications of ABT or 2DG were largely ineffective (Fig. 1e).
Given that p53 is inactive in some of the highly responsive tumor
lines including PPC-1 [27,28,29], we conclude that the combina-
tion-induced apoptosis is p53-independent. The possible reasons
for varied responses will be discussed later.
In order to understand exactly what molecular events take place
when ABT is added to 2DG treated cells, we decided first to
investigate what type of apoptosis is being induced by the
combination of 2DG and ABT.
Combination treatment with 2DG and ABT induces
apoptosis through the intrinsic pathway
It has been reported that the application of 10 nM ABT-737
for just 2 hours causes the mitochondrial outer membrane to
rupture in chronic lymphocytic leukemia (CLL) cells [30]. This
is not a normal phenomenon in apoptosis. Cytochrome c is
usually released through mitochondrial outermembrane pores in
orderly fashion [31]. The destruction of mitochondria takes
place long after cytochrome c release by the activities of fully
activated cell death machineries. When we examined HeLa cells
treated with the 2DG-ABT combination using EM, rupture of
mitochondrial outer membranes was not detected (Fig. 2a). In
ABT-treated cells, however, slight shortening of mitochondria
were observed (Fig. 2b&c); from 0.717+/20.05 mm for untreat-
ed to 0.530+/20.05 mm for ABT only, 0.553+/20.06 mmf o r
2DG+ABT, and slight lengthening of mitochondria in 2DG-
treated cells at 0.844+/20.05 mm. We speculate that since Bcl-
xL and Bcl-w are known to be involved in mitochondrial fusion/
fission [32], ABT may have inhibited their activities. As for the
lengthening of mitochondria under 2DG, it may have created
increased demand for mitochondrial respiration, and to meet
that burden, mitochondria may have become longer. Even
though 2DG and ABT had opposite effects on the length of
mitochondria, they both influenced the physiologies of mito-
chondria. Even though some speculates that mitochondria
fusion/fission machinery may also play a role in apoptosis, the
idea remains controversial [33].
To determine if 2DG-ABT-induced apoptosis is through the
intrinsic pathway, we used wild-type (wt) mouse embryo fibroblasts
(MEFs) and Bax/Bak double knockout (DKO) MEFs. These
DKO cells are lacking the intrinsic pathway. In wild-type MEFs
pre-treated with 2DG, caspase activation was induced within
3 hours of ABT addition (Fig. 3a). However, there was no rapid
caspase activation in Bak/Bax DKO MEFs. Therefore, we
concluded that 2DG-ABT-induced apoptosis occurs by the Bak/
Bax-dependent intrinsic pathway (see also Fig. S5a).
To test whether 2DG also sensitizes tumor cells to the extrinsic
pathway of apoptosis, we used HT1080 cells, in which there is no
cross talk between the intrinsic and extrinsic pathways [34]. Pre-
treatment of HT1080 cells with 2DG for 3 hours did not enhance
Fas-induced apoptosis but lowered caspase activation (Fig. 3b).
Thus, 2DG did not enhance the extrinsic pathway.
Figure 2. Combination of 2DG and ABT-263 does not cause mitochondrial outer membrane rupture. HeLa cells treated with either
10 mM 2DG for 6 hours, 1 mM ABT-263 for 3 hours, or 2DG for 3 hours before adding ABT-263 for an additional 3 hours, or left untreated. a, Cells
were fixed for electron microscopy (see Method). Three cells from each treatment group were examined closely for the length of mitochondria. We
did not observe a single instance of ruptured mitochondrial outermembranes. b, From each cell, a minimum of 12 mitochondria were randomly
chosen for measurement. c, Average lengths of mitochondria became shorter with treatments containing ABT-263 (mean +/2 std dev ). Since ABT-
263/737 binds to Bcl-2 family members, which are known to be involved in mitochondrial fusion/fission, ABT may have altered the balance of
mitochondrial fusion/fission to the fission side (p=0.0001, 95% confidence interval of this difference: from 14.5407 to 37.2513; unpaired t-test).
doi:10.1371/journal.pone.0024102.g002
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caspase-dependent mechanism
A critical step in the intrinsic pathway is the release of
cytochrome c from mitochondria. When 1 mM of ABT-737 was
applied to HeLa cells that had been pre-treated with 2DG for
3 hours, we observed the release of cytochrome c in over 30% of
the cells within the next 3 hours but not in untreated cells or cells
treated with either 2DG or ABT alone (Fig. 3c and Fig. S3).
In canonical mitochondria-dependent forms of apoptosis such
as staurosporine-, etoposide- or UV-induced cell death, the release
of cytochrome c from the mitochondria occurs upstream of
caspase activation and can proceed in the presence of caspase
inhibitors [35,36]. By contrast, during death receptor-induced
apoptosis, caspases activated by these receptors can also cleave the
Bid protein, producing truncated Bid (tBid), with tBid then
inducing Bak/Bax oligomerization and the formation of pores at
the mitochondrial outer membranes through which cytochrome c
escapes. Thus, a pan-caspase inhibitor such as z-VAD blocks
death receptor-induced cytochrome c release from mitochondria.
We found that 2DG-ABT induced cytochrome c release was also
blocked by z-VAD when added synchronously with ABT (Fig. 3c
& d, Fig. S2), yet we showed that the 2DG-ABT induced apoptosis
is Bax/Bak-dependent. This conundrum could be explained by a
Bid-dependent amplification loop in which a small amount of
cytochrome c released by ABT could activate a cascade of caspases
(such as caspases 9,3,6 and 8) in the cytosol, cleaving Bid to
generate tBid, with tBid in turn activating Bak/Bax and causing
further release of cytochrome c from the mitochondria [37,38].
The effects of Bid depletion on 2DG-ABT-induced
apoptosis
We explored whether the hypothesized Bid-based amplification
loop plays a role in 2DG-ABT-induced apoptosis. First, we
determined whether Bid is cleaved during 2DG-ABT induced
apoptosis. In both HeLa and PPC-1 cells, 2DG pre-treatment
followed by the addition of 1 mM ABT-263/737 induced
cytochrome c release from the mitochondria in 3 hours. In both
cell types, the release of cytochrome c was blocked by z-VAD-fmk.
With the PPC-1 line, almost 100% of the cells released
cytochrome c, causing nearly 100% apoptosis. With HeLa cells,
the proportion of cells displaying cytochrome c release within the
first three hours was approximately 30% (Fig. 3c). Truncated tBid
was seen 3 hours after the addition of ABT in PPC-1 and HeLa
cells (Fig. 4a, data not shown). tBid was absent in cells treated with
2DG alone. When z-VAD-fmk was added with ABT, the cleavage
of Bid was blocked.
To determine what effect, if any, Bid has on 2DG-ABT-induced
apoptosis, we depleted the Bid protein by siRNA. 2DG-ABT-
induced apoptosis was largely blocked in Bid-depleted PPC-1 cells.
Bid depletion increased the percentages of viable cells by ,8-fold
Figure 3. 2DG-ABT induced apoptosis is a non-canonical mitochondria-dependent form of apoptosis. a, Wt, and Bax/Bak DKO MEFs
were treated with 10 mM 2DG for 3 hours before the addition of 3 mM ABT-263 for 3 hours. 3 hours later, cells were harvested for caspase activity
assays. (See also Fig. S5a). b, HT1080 cells were treated with or without 2DG for 3 hours. Then cells were treated with either 1 mM STS or anti-Fas
(CD95) antibody at indicated concentrations (mg/ml). Cells were harvested 3 hours after, and assayed for caspase activity. Interestingly, 2DG seems to
have interfered with Fas-induced apoptosis. In repeated experiments, we observed consistently lower rates of caspase activation in 2DG pre-treated
cells, but the degrees of inhibitory activity varied from experiment to experiment. We are not sure of its cause. c, For the first 3 hours, HeLa cells were
either treated with 10 mM 2DG or left untreated and then treated with 10 mM z-VAD, 1 mM ABT-737, both, or neither for 3 more hours. The cells were
fixed and stained for DNA (red) and cytochrome c (green) and examined for loss of cytochrome c staining, as described in Methods. Bar indicates
100 mm. The representative images are shown in Fig. S3. This graph shows the percentage of cells with loss of cytochrome c staining. The
combination treatment had higher rates of cells with released cytochrome c (p=0.008 by unpaired t-test ). d, Cells treated as in c were fractionated
and cytosolic fractions were analyzed by western blots.
doi:10.1371/journal.pone.0024102.g003
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cytochrome c correlated with apoptotic rates (Fig. 4c). Thus, the
Bid-dependent amplification loop is required for efficient 2DG-
ABT induced apoptosis. Bid depletion had a similar impact on
apoptosis induced by 10 mM ABT-263 but the impact was less on
STS-induced apoptosis (data not shown and Fig. 4b & c). Lastly,
Bid KO MEFs also displayed reduced sensitivity to 2DG-ABT
treatments (Fig. S5a). We concluded that Bid plays a significant
role in 2DG-ABT-induced apoptosis.
Search for 2DG effectors
Since 2DG-ABT combination-induced apoptosis is Bax/Bak-
dependent, we examined the effects of 2DG on Bax and Bak
during the three-hour pre-incubation. Some cells cultured under
hypoxic conditions or in glucose-depleted media for extended
periods, become sensitized to apoptosis [39,40,41]. Although no
universal marker exists for cellular sensitivity to apoptosis, Bax is
known to translocate to the mitochondria prior to apoptosis and
necrosis in some cases [41]. Bax translocation also seems to be a
distinct step, and not necessarily concurrent with its activation
[42]. However, in HeLa cells treated with 2DG alone, Bax
translocation was not induced for at least 16 hours (Fig. S4a).
Thus, unlike in cells cultured in glucose-depleted media, Bax
translocation does not take place during the 2DG pre-incubation
period. Furthermore Bax knockout MEFs responded to the 2DG-
ABT-combination treatment (Fig. S5a), suggesting that Bax may
not play a critical role in priming of cancer cells by 2DG. Of
course, in the absence of Bak, Bax is already be at mitochondria,
playing the role of Bak, and Bax may be activated by a different
mechanism when it is at mitochondria [43].
Because 2DG can affect glycosylation, 2DG-treatment might
induce ER stress. Indeed, expression of the ER stress marker,
Grp74, was observed in HeLa cells treated with 2DG for 2 to
4 hours (Fig. 5b and Fig. S4b). We hypothesized that if 2DG is
acting through ER stress, we might be able to sensitize HeLa cells
for ABT-induced apoptosis by pre-treating them with other ER
stress inducers such as thapsigargin. However, this was not the
case (Fig. S4c). Thus, 2DG appears to sensitize tumor cells to Bcl-2
antagonists through mechanisms that do not depend on glucose-
depletion or ER stress.
2DG disrupts Bak-Mcl-1 association, priming cells for
ABT-induced apoptosis
It has been reported that culturing cells in glucose-depleted
medium or in the presence of 2DG for extended time (24 hours or
longer), could lower cellular ATP concentrations and prime
various cells for apoptosis [39,40,44]. During this induced ATP
insufficiency, translation of anti-apoptotic Mcl-1 is hampered,
lowering protein levels of Mcl-1 and priming cells for apoptosis.
We tested whether 2DG lowers Mcl-1 protein levels. As mentioned
earlier, the decreases in cellular ATP concentration is very slight
during the first 8 hours with 2DG (Fig. 5a). Furthermore, no
significant changes were observed in the levels of Mcl-1 and
several other anti- and pro-apoptotic proteins during the first eight
hours of 2DG exposure (Fig. 5b). The levels of Mcl-1 also
remained unchanged after ABT addition in HeLa, PPC-1 and
other cells (Fig. 5c and Fig. S4d). Altogether, these experiments
suggest that ABT-263/737 induces apoptosis without depleting the
Mcl-1 protein. We cannot exclude the possibility that more subtle
changes such as phosphorylation or other post-translational
modifications of Mcl-1 and other anti-apoptotic proteins occurred
during 2DG-incubation, which may be responsible for the
sensitizing effect of 2DG. Indeed, we found that even though
Mcl-1 protein levels seem unchanged, Mcl-1-Bak association was
lost during 2DG pre-incubation, and remained absent during the
subsequent incubation with 2DG and ABT (Fig. 5d). Since both
Figure 4. The Bid-based feedback loop is required for efficient 2DG-ABT induced apoptosis. a, Bid is activated during 2DG-ABT
induced apoptosis. Western blots of PPC-1 cell lysates treated with 10 mM 2DG for 0–6 hours (left panel), with either 1 mM ABT-263 alone or ABT-
263+10 mM z-VAD for the last 3 hours (right panel), probed with the anti-tBid antibody (upper panels), anti-Opa1 antibody (middle panels), and anti-
alpha-tubulins (lower panels). Note: the loss of Opa-1-L was used as a marker for remodeled mitochondrial cristae during cytochrome c release from
the mitochondria [34]. b, The effects of Bid depletion on 2DG-AB-induced apoptosis. Insert: western blots of PPC-1 cell lysates, mock
transfected (left lane) or transfected with Bid siRNA (right lane). Bid (+) and Bid (2) PPC-1 cells were treated with either 2DG, ABT-263 (1 mM), both,
10 mM ABT-263, or left untreated for 24 hours. The viable cells were counted and the increase/decrease over the input numbers were graphed. c, In
PPC-1 cells either pre-treated with 2DG for 3 hours or without pre-treatment, then 1 mM ABT-263 or 1 mM STS was added for three hours, and
cytosolic fractions were analyzed by western blots. In parallel experiments, Bid-depleted PPC-1 cells were treated with the combination of 2DG and
ABT-263 or with STS and analyzed (designated as Bid kd, last 2 lanes). Cells were harvested 3 hour after ABT/STS treatment, and cytosolic fractions
were analyzed with western blots.
doi:10.1371/journal.pone.0024102.g004
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of Mcl-1-Bak association during 2DG incubation can sensitize cells
because ABT can now effectively bind Bcl-xL and free Bak. Earlier
we noted that HL-60 is sensitive to ABT-737 despite having large
amounts of Mcl-1 expressed. It was also shown that anti-Bak
antibody failed to co-precipitate Mcl-1 even though it can co-
precipitate Bcl-2 [26]. Thus the reason for its sensitivity might be
the absence of Bak-Mcl-1 complex. We do not know why Bak does
not bind to Mcl-1 in HL-60 cells. Currently we are investigating
the possible molecular changes to Bcl-xL and Mcl-1 disruptive to
their association.
Taken together, we propose the following model for 2DG-ABT
induced apoptosis in cancer cells (Fig. 6): 2DG induces changes in
Bak or Mcl-1 so that they can no longer associate. ABT binds to
the BH3 pocket of Bcl-xL, breaking its hold on Bak. Released Bak
forms oligomers, releasing a small amount of cytochrome c.
Released cytochrome c now activates caspase cascades, generating
tBid which can induce full-scale outer membrane pore formation
on mitochondria. A large-scale release of cytochrome c triggers
full-scale apoptosome formation and cell death. This model is
supported by our findings.
2DG activates PI3K and generates a pro-survival signal
It has been reported that 2DG can activate multiple signal
transduction cascades, activating well-known kinases such as
PI3K, MAPK and IKK that phosphorylate over 30 proteins,
some of which are known to be involved in apoptosis [5,6]. Thus it
is possible that one of these signals is responsible for the loss of
Bak-Mcl-1 association. However, these reports caution that 2DG
can also activate a pro-survival pathway via PI3K and the
phosphorylation of AKT; thus, adding 2DG could hinder, rather
than facilitate apoptosis, depending on the cell type. Indeed, we
have consistently observed lower rates of STS-induced apoptosis
when cells were pre-incubated with 2DG (Fig. 3a and Fig. S2c).
We thus tested whether pro-survival signals are generated in HeLa
cells during 2DG-ABT induced apoptosis by using LY294002, a
PI3K inhibitor, to ascertain if we could block this signal. With the
addition of LY294002, an almost three-fold increase in caspase
Figure 5. 2DG disrupts Bak-Mcl-1 association, priming cancer cells without lowering protein levels of Mcl-1. a, The effect of 2DG on
cellular ATP levels. The amounts of ATP were measured during HeLa cell culture with 10 mM 2DG in the presence of 25 mM glucose in DMEM
supplemented with 10% serum. b, Protein profiles during 2DG incubation of HeLa cells. Samples were taken from HeLa cells treated as in a,
and various protein contents of pro- and anti-apoptotic proteins were analyzed by Western blots. In this experiment, we see increases in Bcl-xL for the
first hour. When we repeated the experiment twice, Bcl-xL levels remained the same. c, Mcl-1 levels remained unchanged during 2DG-ABT-
induced apoptosis. PPC-1 cells were treated with 10 mM 2DG for 6 hours, 1 mM ABT-263 for 3 hours, or 10 mM 2DG for 6 hours of which the last
3 hours were incubated with 1 mM ABT-263. d, Bak and Mcl-1 do not co-precipitate in 2DG treated cells. PPC-1 cells were treated as in c. Bak
and Mcl-1 were immunoprecipitated by specific antibodies conjugated to Protein G-Sepharose and the co-precipitated proteins were analyzed by
Western blots. Left Upper Panels, Bak co-precipitates, Right Upper Panels, Mcl-1 co-precipitates, and Left Lower Panels, Protein G-Sepharose
precipitates. For technical reasons, we could not immunoprecipitate Bcl-xL and analyze its content.
doi:10.1371/journal.pone.0024102.g005
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confirming that 2DG generates a pro-survival signal through PI3K
in HeLa cells. 2DG also induced phosphorylation of ATK in
HeLa cells (data not shown). Thus, 2DG seems to be sending
complicated and often conflicting signals (Fig. 6). The way in
which cells respond to 2DG might determine if they will become
sensitized or resistant to apoptosis. We thus decided to examine
how commonly available cell lines and primary cells would
respond to the 2DG-ABT combination treatment.
Most cancer cells responded to the 2DG-ABT treatment
Most cancer cells tested responded well to the combination
treatment; apoptosis was induced in most cells with just 1 mM
ABT-263/737. The list of 2DG-ABT sensitive cells includes cells
from leukemia (RS(4;11), BP3), cervical cancer (HeLa), prostate
cancer (PPC-1/PC-3), hepatocarcinoma (HepG2), breast cancer
(MCF-7), and most small lung carcinomas. However, cells with
low glucose transporter activities such as confluent NIH3T3 cells
and CLL cells that do not grow in culture could not be sensitized
by 2DG for ABT-induced apoptosis. Small-cell lung carcinoma-
derived cell lines, on the other hand, grow well in culture, and
most of them are sensitive to ABT [8,45]. The NIC H82 cell line is
a well-studied exception to this rule, but why it is resistant to ABT
remains unclear [8,46]. However, we now know that activation of
the Bid protein is necessary for efficient apoptosis induction by
ABT, and the CASP8 gene encoding the Bid-activating capsase-8
enzyme is deleted in NCI H82 cells [47,48]. Thus, it seems likely
that the absence of caspase-8 makes NCI H82 cells resistant to
ABT-induced apoptosis.
Pancreatic cancer cells are highly resistant to apoptosis. Despite
our repeated attempts at inducing apoptosis in PANC-1 pancreatic
cancer cells, the 2DG-ABT treatment failed to induce apoptosis.
PANC-1 cells express Bid, Bcl-2 and Bak, and cleaved Bid is
observed in TNF-treated cells, and these cells have active glucose
transporter(s) - all the conditions necessary for 2DG-ABT induced
apoptosis. Thus, these conditions are clearly not sufficient. We are
trying to discover why these cells are so highly resistant. We are
also setting up screens to identify apoptosis inducers specific for
2DG-treated pancreatic cancer cells.
2DG improves anti-tumor activity of ABT-263 in a
xenograft model of human prostate cancer
Previous work demonstrated that either 1 g/kg of 2DG [49,50]
or 100 mg/kg of ABT-263 [9] could safely be injected into mice.
To test the safety of the combination, we treated wild-type
C57BL/6 mice with intraperitoneal injection of 0.5 g/kg of
2DG+/20.5 g/kg of glucose in the morning, and 100 mg/kg of
ABT-263 in the afternoon. The combination treatment produced
only a few side effects, including mild lymphopenia and reversible
thrombopenia, similar to ABT-263 alone (data not shown)
[9,51,52].
For xenograft implants, we chose a highly chemorefractory
tumor line PPC-1 [27,28,29,53,54,55,56]. Five million PPC-1 cells
were injected into each athymic nude mouse, and the mice were
treated three times a week for 3 weeks from day 9 to day 27 with
the following regimens: Group A mice received buffer only, Group
B mice received 2DG only, Group C mice received ABT-263 only,
Group D mice received 2DG in the morning and ABT-263 in the
Figure 6. Model of 2DG-ABT Induced Apoptosis. a, 2DG is specifically taken up by cancer cells through a glucose transporter. Once inside, it is
phosphorylated and becomes a hexokinase inhibitor. At the same time, it activates several signal transduction cascades. One of them is IGFR-PI3K-
mTOR-AKT pro-survival pathway. Through another cascade activation, Bak-Mcl-1 association is lost. When ABT is added 3 hours later, it can bind to
Bcl-xL and disrupts its association with Bak. b, Freed Bak oligomerizes, releasing a small amount of cytochrome c into the cytosol. It activates
cascades of caspases 9-3-6-8 and caspase 8 cleaves Bid, generating BH3 only tBid protein. Since tBid can dissociate Bak-Mcl-1 and Bak-Bcl-xL
association, it induces mitochondria outermembrane pore formation through which more cytochrome can be released. Released cytochrome c
recruits Apaf1, caspase 9 and dATP, forming a ‘‘death executioner’’ apotosome complex.
doi:10.1371/journal.pone.0024102.g006
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mix in the morning and ABT-263 in the afternoon. After
treatment with 2DG only, there was only a 5- to 6-day delay in
tumor growth (Fig. 7a). In contrast, except for one mouse in
Group E, the tumors in all of the mice in Groups C, D, and E
regressed during treatment. The rates of tumor regression among
these groups were roughly similar. However, when treatments
were concluded at day 27, tumors began to grow in mice in
Groups C and D, such that all these mice required euthanasia
before day 50. The mice in Group E fared better, and most of
their tumors remained small until day 50; these mice survived an
average of 2 weeks longer than the mice in Groups C and D
(Fig. 7b). The mouse experiments were repeated twice with very
similar results (Fig. S6). These results concur with our tissue
culture results, demonstrating the clear advantage of the
combination treatment. When we surveyed literature on treat-
ments of PPC-1/PC-3 tumor bearing mice, we only found
treatments that had arrested or slowed tumor growth (cytostatic
effects) – and we alone had the treatment to induce tumor
regression (cytoxic effect) [27,55,56,57,58,59]. To summarize,
these preclinical data suggest that deoxyglucose-ABT-263/737
combination therapy may provide a safe and effective alternative
to the genotoxin-based chemotherapies currently used for
treatment of cancer.
Discussion
In order to induce apoptosis in cancer cells, genotoxin-based
therapies activate cell cycle checkpoint and genomic surveillance
programs. Rapidly dividing cancer cells are also under pressure to
compromise those same programs. As cancer progresses and
accumulates more mutations, it seems natural that it becomes
more resistant to genotoxin-based therapies. Therefore, to
effectively treat advanced cancers, we need a different approach.
Uncontrolled cell growth is one of the defining features of
cancer. Indeed, most cancer cells have multiple mutations in the
Figure 7. Treatment of tumor-bearing mice with 2DG-ABT combination. Five million PPC-1 human prostate cancer cells were xenografted
onto nude mice as described in the text and the method. a, Mice Tumor volumes were measured in mice (n=7 per group) treated with diluent only
(group A), 2DG (group B), ABT-263 (group C), 2DG plus ABT-263 (group D), or 2DG mixed with D-glucose plus ABT-263 (group E), as explained in the
text, where drugs were administered 3 times weekly between day 9 and 27 (gray rectangles). b, Survival of tumor-bearing mice was determined at
various times post-inoculation with PPC-1 cells. The % of surviving mice is indicated from groups A-E (n=7 per group). The difference of survival days
between Group C & D versus Group E is p=0.0283, 95% confidence interval of this difference: from 220.98 to 21.36 by unpaired t-test.
doi:10.1371/journal.pone.0024102.g007
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activated growth-signaling pathways, we could not only arrest the
cell growth, but also induce apoptosis in cancer cells. In fact, the
oncogenic addiction paradigm postulates that cancer cells rely on
just one oncogene to tip the balance between the induction of
rapid cell cycle and the activation of cell cycle checkpoint that
induces apoptosis [60,61,62]. Based on the oncogene addiction
paradigm, targeted therapies deploy specific inhibitors of the
presumed key oncogenes to treat particular cancer types [63]. The
oncogenic addiction concept gained credence when Imatinib
(Imatinib mesylate; commercial name Gleevec, originally STI571),
a specific inhibitor of bcr-abl protein expressed in chronic myeloid
leukemia (CML), successfully treated CML, achieving 5-year
incident-free survival rates around 90% in most studies [64,65].
Furthermore, because inhibitory effects of Imatinib are limited to a
few kinases, Imatinib had shown few side effects.
Since the development of Imatinib, many more targeted drugs
have been tested in clinical trials. These trials showed that many
promising drugs induced rapid tumor regression with little side
effects, resulting in near complete cancer remission within a few
weeks. However, all too often, cancer returned within a year in
treatment-resistant forms [66]. There were two ways that cancer
gained resistance to the treatment: 1) mutation in the targeted
oncogene and 2) gain of function mutations on the downstream
effectors that constitutively activate them [67,68,69]. These
mutations may have been in a small number of cells in the initial
tumor mass, or they may have developed during the pro-longed
treatment. Trying to remedy the situation, more targeted drugs
were developed in some cases [70].
With knowledge gained through clinical trials, the oncogene
addiction model was revised [71]; if we look at carcinogenesis as a
step-by-step mutational process, oncogene addiction must occur
after the critical oncogene activation and before the constitutively
activating mutations of its down-stream effectors. Of course,
during cancer development, there could be more than one
oncogene addiction phase. In a later phase, cancer cells may
depend on a different oncogene for cell growth and survival. Thus
there may be another opportunity later on to treat cancer with a
different targeted drug.
Since tumors tend to be a heterogeneous mix of cells at different
stages of cancer development, and if targeted drugs can only be
effective at particular stages, then using a single targeted drug
might only eliminate a fraction of cancer cells. Thus it will
probably take multiple targeted drugs to completely eliminate
most cancer types. Incoming results from the recently established
Cancer Genome Atlas Project indicate that a typical solid tumor
carries as many as 30–80 somatic mutations [72], suggesting
difficulties faced trying to choose the right combination of targets
in most cancer types. In the future, however, genome sequencing
of cancer cells from individuals would enable us to identify all the
somatic mutations for each individual cancer. Protein profiles of
these same tumor cells could also be built. Based on the signaling
pathways determined from these data, the treatment for each
individual could be customized. This would be the height of
personalized medicine, but even in the future, this could be an
enormously expensive option.
Despite the advances made in personalized medicine, we believe
the ideal cancer therapy should still be the therapy that is
applicable to all sorts of cancer types at many stages of
development, including highly metastasized late stages of cancer.
We believe the ideal cancer therapy may be possible by combining
deoxyglucose with drugs targeting mitochondria for direct
mechanical activation of mitochondrial outermembrane pores
(MOMP). Once MOMP is activated, cytochrome c is released into
cytosol, activating apoptosomes, the death executioner. Thus by
activating steps very close to the final step in apoptosis, we are
lowering the risks of cancerous cells developing therapy-resistant
mutations.
There are two unique features of deoxyglucose that makes it an
ideal chemotherapeutic partner. The first is the almost exclusive
uptake of deoxyglucose by cancer cells (see the introduction). The
second feature is that it primes cells for mitochondria-dependent
apoptosis. Bak is an important component of mitochondrial
outermembrane pores (MOMP). It is normally sequestered in
complexes with Mcl-1 and Bcl-xL. We have shown that in cells
treated with deoxyglucose, Mcl-1 dissociates from Bak, leaving
only Bcl-xL to sequester Bak from forming MOMPs. Antagonists
of the Bcl-2 family, such as ABT-263 and ABT-737, likely
dissociate Bcl-xL from Bak, inducing apoptosis at a submicromolar
concentration.
Deoxyglucose-ABT-263 combination therapy was shown to be
effective in eliminating cancer cells representing many different
cancer types and covering different stages of development. Using
human tumor cells xenografted onto nude mice, we showed that
the combination therapy induced tumor regression in checkpoint
defective (point mutation in p53), chemo-resistant, PTEN deleted,
late stage cancer cells. In mice, the combination therapy
specifically targeted tumor cells and eliminated them safely and
more efficiently than 2DG or ABT alone. Even though 2DG-ABT
combination therapy is still at an early stage of development as
cancer therapy, it is meeting all the criteria for an all purpose-
multifaceted cancer therapy. Thus we are hopeful that we may
have found a simple solution to a very complex problem of treating
cancer.
Materials and Methods
Reagents
2-Deoxy-D-glucose was purchased from Sigma (D3179).
Ethyl 3-Bromopyruvate was purchased from Lancaster Chem-
icals (Cat. L00582).
z-VAD-fmk (benzoyl-Valinyl-Alaninyl-Aspartyl-fluoromethyl-
ketone) was purchased from BD Bioscience.
To stimulate death-receptor pathway in HT1080 cells, we used
anti-Fas mouse antibody from MBL, clone CH-11 (CD95),
0.5 mg/ml used at 3 and 0.3 mL/ml.
ABT-737 was purchased from Selleck Chemicals or provided by
Abbott Laboratories, Inc.
ABT-263 was purchased from Chimietech.
Staurosporine, Thapsigargin, and Tunicamycin, were pur-
chased from EMD Bioscience.
PI3K inhibitor, LY294002, was purchased from Merk Chem-
icals.
Cell lines
Prof. Koji Yamada, Kyushu University, generously provided
MCF7, HepG2 and PANC-1. Bid KO MEF cells were a kind
gift from Prof. Atan Gross, The Weizmann Institute of Science.
NCI H82 cells were kind gifts from Prof. Jun Yokota, National
Cancer Research Center, Tokyo. RS(4;11) cells was a kind gift
from Prof. Hidemistu Kurosawa, Dept. of Pediatrics, Dokkyo
Medical University, Mibu, Tochigi, Japan. Prostate cancer cell
line PPC-1/PC-3 (Cytogenet Cell Genet 1993;62:183-4), and all
othercellswere fromSanford-BurnhamMedicalResearchInstitute.
All the experiments in the article were performed using either
ABT-737 or ABT-263, and then repeated using the other agent,
except for the mouse xenograft work and the EM work for which
only ABT-263 were used.
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We tested several conditions such as the length of pre-
incubation and the concentration of deoxyglucose in the media
(Fig. S2 and data not shown), and developed the following
protocol. To cells cultured in appropriate medium, add 2DG at a
molar ratio 0.5:1.0 2DG to glucose, and incubate the cells for three
hours before ABT addition. In DMEM that contains 2 g/L of
glucose, we typically used 10 mM 2DG, while in high glucose
medium, we used 20 mM 2DG. We regularly used 1 mM ABT-
263/737 for the 2DG-ABT combination for cancer cells and
3 mM for MEFs. For a single-agent application, we used 10 mM
ABT for cancer cells and 30 mM ABT for MEFs.
Western blotting and immunoprecipitation
We usually run either 12.5% or 4–20% gradient gels for
Western Blots, except for detecting loss of long isoforms for Opa1
(8% SDS-PAGE gels), and separating Bak protein from IgG Light
Chain (15% SDS-PAGE gels). The following antibodies were used
for Western Blots: anti-Opa1 mouse mAb from Transduction
Lab (Cat. 612606), anti-Cyt C mouse mAb from BD Bioscience
(Cat 556433), anti-Bid mouse mAb from Santa Cruz (5C9)
0.1 mg/ml, anti-Bid Rabbit Polyclonal Ab from Thermo
Scientific (Cat PA1-84831), anti-Bak NT Rabbit polyclonal Ab
from Millipore, anti-Bax and anti-Mcl-1 Rabbit Polyclonal Abs
were previously described [Krajewski, et al 1994 Am. S. Pathol 145–
515; Krajewski S et al 1995 Cancer Res 55: 4471], anti-Grp78
Rabbit Polyclonal Ab from ABR (Cat. PA1-014), anti-PKM2
antibody gifted from the Lewis Cantley laboratory. To immuno-
precipitate of Bak and Mcl-1 proteins from PPC-1 cells, we used
mitochondria-enriched fraction [20], re-suspended in buffer
containing 1% Triton X-100 as described [20]. To immunopre-
cipitate Bak and Mcl-1 proteins, antibodies against them (anti-Bak
NT Rabbit polyclonal Ab from Millipore, and Anti-Mcl1 Rabbit
Polyclonal Ab from Krajewski) were conjugated to Protein G-
Sepharose, mixed with lysates, and incubated overnight on a
rotating platform. To separate Bak from IgG Light Chain, we run
immunoprecipitates in 15% SDS-PAGE. For detection of Mcl-1,
we run precipitates in 12.5% SDS-PAGE.
Immunofluorescence microscopy
Cells were treated as described [31]. Briefly, cells were fixed in
3.7% formaldehyde for 20 min, washed in PBS, and permeabi-
lized with 0.5% Triton X-100. Nonspecific binding was blocked by
incubating cells in 0.2% gelatin/PBS for 30 min. Cytochrome c
staining was performed using a primary antibody against
cytochrome c (clone 6H2.B4, Cat 556432, BD Science) and a
fluorescent secondary antibody conjugate, goat anti-mouse IgG,
AlexaFluor 568 (Molecular Probes). Images were captured by a
MRC 1024 SP BioRad Laser Point Scanning Confocal Micro-
scope. For Bax translocation studies, we used anti-Bax Rabbit
Polyclonal Ab [Krajewski, et al 1994 Am. S. Pathol 145–515;
Krajewski S et al 1995 Cancer Res 55: 4471].
Electron microscopy
Cells were prepared and the electron microscopy was per-
formed following the procedure described in ‘‘Elevated hydrostatic
pressure triggers release of OPA1 and cytochrome C, and induces
apoptotic cell death in differentia t e dR G C - 5c e l l s ’ ’ ,[ J uW K ,K i mK Y ,
Lindsey JD, Angert M, Patel A, Scott RT, Liu Q, Crowston JG,
Ellisman MH, Perkins GA, Weinreb RN. Mol Vis. 2009;15:120-34.]
Bid siRNA
From Qiagen Cat. No SI02661911 (59-AGACAAUGUUAAA-
CUUAUATT-39 &5 9-UAUAAGUUUAACAUUGUCUTT-39)
HeLa and PPC-1 cells were transfected with siRNA above and
using Lipofectamine 2000 (invitrogen) using the manufacture’s
protocol. We used mock transfection for controls. For both cells,
transfections were done twice, 24 hours apart. Cells were used a
day later for western blots and apoptosis assays.
Apoptosis assay
RS(4;11) cells were stained with Annexin V-FITC (Invitrogen
PHN1008) and analyzed by FACSort (BD). HeLa cells were
stained with Annexin V-APC (Invitrogen A35110) and analyzed
by BDFACSCanto according to the manufacture’s instruction.
Yoav Alterman and Shinichi Kitada at Sanford-Burnham Medical
Research Institute performed FACS analysis.
ATP measurement
ATPlite solution (10 mL for 200 mL cell culture) was added, and
a luminomitor (Monolight 3096; BD Biosciences) was used to
measure luminescence.
Caspase assay
Cells grown to 80% confluency in 6 well dishes (diameter
34.9 mm) were washed in PBS and then incubated in appropriate
media (e.g., DMEM with 12 mM glucose for HeLa cells). 5–
10 mM 2DG was added to the indicated samples, and 3 hours
later, 1 mM ABT-737 was added to the indicated samples. 3 hours
later, cells were (1) washed once in PBS, (2) incubated in 0.05%
trypsin, 0.2 g/L EDTA in Hank’s Balanced Salt, (3) diluted in
106volume DMEM containing 10% serum and trypsin inhibitor,
(4) cells were span-down by centrifugation), (5) washed once with
PBS, (6) pellets were re-suspended in 100 mL lysis buffer [20 mM
Hepes, pH 7.4, 0.5% Triton X-100, 0.5 mM EDTA, and
150 mM NaCl] , (7) incubated on ice for 10 minutes, and then
centrifuged at 10,000 g to remove the insoluble fraction. 10 mLo f
supernatant was diluted in 100 mL buffer [50 mmol/L HEPES
(pH 7.4), 100 mmol/L NaCl, 0.1% CHAPS, 10 mmol/L DTT,
1 mmol/L EDTA, and 10% glycerol], containing 100 mmol/L
Ac-DEVD-AFC and caspase activities were measured by a
spectrofluorimeter at 37uC taking measurement for 20 min.
Increases in relative fluorescence units [RFU] per minute were
determined from the graph.
Cell fractionation
Cell were first washed in PBS twice, then re-suspended in buffer
containing 10 mM Hepes (pH 7.4) 10 mM KCl, 1 mM EDTA,
1 mM EGTA and 250 mM trehalose, at one million cells per
0.5 ml. They were incubated on ice for 30 min. Cells were dounce
or needle homogenized until a small sample of cells showed
roughly 40% trypan blue positive. Cells were centrifuged at
10,000 g for 5 minutes for three times, each time collecting the
supernatant. The supernatant was almost exclusively cytosolic
fractions.
Statistical analysis
Statistical analysis was performed at Graphpad, http://www.
graphpad.com/quickcalcs/ttest1.cfm?Format=C.
Mouse xenograft
Mice were maintained under specific pathogen-free conditions
in accordance with guidelines by the Association for Assessment
and Accreditation of Laboratory Animal Care International.
CCHMC is credited through the Animal Welfare Assurance
(#A3108-01). All animal experiments were carried out in strict
accordance with animal protocol #8C03021 that was approved
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with the guidelines by the Association for Assessment and
Accreditation of Laboratory Animal Care International and the
recommendations in the Care and Use of Laboratory Animals of
the National Institute of Health.
Eight-week-old male Athymic Nude mice (Hsd:Athymic Nude-
Fox1
nu, Harlan, Indiana, USA) were engrafted with 5610
6 PPC-1
cells in 0.1 ml 50% matrigel (BD Bioscience) s.c. in the upper left
flank. Nine days later tumor-bearing mice were randomly divided
over all treatment groups. ABT-263 was formulated in 10%
ethanol, 90% Cremophor (Sigma) and glucose/2-Deoxyglucose in
PBS. Mice received either Cremophor only (0.2 ml i.p.), ABT-263
(2 mg/0.2 ml i.p.), 2-deoxyglucose (10 mg/0.2 ml i.p.), or a mix of
glucose/deoxyglucose (10 mg each in a total volume of 0.2 ml
i.p.). For combination treatments, ABT-263 was given 3 hr after
the other agents. Tumor size was measured two to three times
weekly by electronic calipers (volume=(length6width
2)/2). All
studies used 5–10 mice per group. Statistical comparisons of tumor
growth rate and survival used the Wilcoxon rank sum test and the
Mantle-Cox log-rank test respectively. Mice were maintained
under specific pathogen-free conditions in accordance with
guidelines by the Association for Assessment and Accreditation
of Laboratory Animal Care International.
Supporting Information
Figure S1 Effects of 2DG on ABT-263 induced apoptosis.
a, RS(4;11) cells pre-treated with 20 mM fructose or 10 mM 2-
deoxy-D-glucose in regular RPMI medium containing 12 mM
glucose, for 1 hour before the addition of ABT-263 at indicated
concentrations. 24 hours later, cells were analyzed by trypan-blue
dye exclusion assay. b, HeLa cells were pre-treated for 1 hour either
with or without 10 mM deoxyglucose in DMEM containing 12 mM
glucose, beforeadding indicated amounts of ABT-263, or 1 mMS T S .
24 hours later, cells were assayed by trypan-blue dye exclusion assay.
% of blue dead cells were tallied against 100% input.
(TIFF)
Figure S2 Optimizing conditions for 2DG-ABT induced
apoptosis. a, Comparable sensitization of tumor cells to
ABT-737 and ABT-263 by 2DG. HeLa cells were pre-treated
with 10 mM 2DG for 3 hours, then treated with either ABT-737
or ABT-263 for 3 hours at the indicated concentrations (mM).
Caspase activities were compared. Data represent results of
triplicate samples (mean 6 std dev; n=3). b, Conditions for
2DG treatment. HeLa cells grown to 80% confluency in 6 well
dishes (diameter 34.9 mm) were washed in PBS and incubated in
10% serum in DMEM without glucose or with 2 g/L of glucose
(12 mM glucose). Immediately, 10 mM 2DG was added to the
indicated samples, and 3 hours later, 1 mM ABT-737 was added
to the indicated samples. 3 hours later, cells were harvested and
caspase activities were measured (relative fluorescence units [RFU]
per min per6mg of lysates, see Methods). c, HeLa cells were pre-
incubated with 10 mM 2DG for indicated lengths of time before
1 mM ABT-263 or 1 mM STS was added. Caspase activities were
measured three hours later. All data represent mean 6 std dev
(n=3). d, HeLa cells were pre-treated with 10 mM 2DG for
indicated length of time before the addition of 1 mM ABT-737.
24 hours later, dead cells were counted by Trypan Bleu Inclusion
Assay, and % of dead cells were graphed.
(TIFF)
Figure S3 Cytochrome c release is by 2DG-ABT and is
blocked by z-VAD. HeLa cells were treated with or without
2DG for three hours, followed by 1 mM ABT-737+/210 mMz -
VAD for 3 hours. Cells were fixed and nuclei were stained by
propidium iodine (red), while cytochrome c was stained with anti-
cytochrome c antibody followed by FITC-conjugated secondary
antibody (green).
(TIFF)
Figure S4 Deciphering how 2DG is priming cancer cells
for ABT-induced apoptosis. a, Bax translocates to
mitochondria after 16 hour-incubation with 10 mM
2DG. HeLa cells were treated with 10 mM 2DG in the presence
of 12 mM glucose for 0–16 hours. Cells were fixed and examined
at 0, 4, 8 and 16 hour point, and examined for translocated Bax.
% of cells with mitochondrial Bax was graphed (Left). Represe-
tative images of diffused cytosolic Bax (right upper panel) and
mitochondria-localized Bax (right lower Panel) were shown. b&
c, analysis of glycolysis inhibitors and role of ER stress.
b, HeLa cells were incubated with 10 nM Thapsigargin or 5 mg/
ml Tunicamycin in media containing
35S-methionine, for 0–
8 hours. Total lysates were fractionated by 4–16% SDS-PAGE,
transferred to membrane and exposed to x-ray film. Induction of
ER stress marker, Grp74, is seen at 4–8 hours. The identity of the
band was also confirmed by immunoblotting using a Grp74-
specific antibody. We did not detect any other changes in these
samples. c, Thapsigirgin did not prime HeLa cells for
ABT-induced apoptosis. HeLa cells were either treated with
10 nM Thapsigargin for 4 hours or left untreated before addition
of 0–3 mM ABT-737 or 1 mM STS. Caspase activities were
measured 3 hrs later (mean 6 std dev; n=3). d, Effects of 2DG
& ABT on Mcl-1 on various cell lines. Cancer cells, PPC1,
MCF-7, HepG2 and RS(4;11) were treated with 10 mM 2DG for
0–6 hours, 1 mM ABT-263 for 3 hours (ABT only), or pre-treated
with 2DG for 3 hours followed by the addition of 1 mM ABT-263
for 3 hours (Both). Samples were analyzed by Western blot for
Mcl-1 and a-tubulin.
(TIFF)
Figure S5 The factors that affect 2DG-ABT induced
apoptosis. a, Effects of 2DG, ABT-263 and combination
treatments on MEFs. Wt and Bax/Bid single KO MEFs and
Bax/Bak DKO MEFs were treated with or without 2DG for 3 hours,
then 3 mM ABT-263 was added in indicated cells,and 24 hourslater,
viable cells were counted by trypan blue dye exclusion methods. b,
PI3K inhibitor enhanced 2DG-ABT induced apoptosis.
HeLa cells were treated with or without 10 mM LY294002 (PI3K
inhibitor) for 5 minutes. Then cells were subjected to the standard
2DG/ABT-263 treatment. Cells were harvested 3 hours after ABT
addition and caspase activity was assayed.
(TIFF)
Figure S6 Additional mouse xenograft data. The exper-
iment presented in Fig. 7 was repeated with a larger number of
mice for each group. Otherwise, all the materials and conditions
were the same. a, Tumor volume was measured using external
calipers for each mouse. The rectangle indicates the period during
which drug treatment was administered. b, The percentage of
surviving mice is indicated.
(TIFF)
Information S1
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